Last reviewed · How we verify
Allr3 — Competitive Intelligence Brief
marketed
The pharmacological class of ALLR3 is not specified.
The molecular target of ALLR3 is not specified.
Oncology
Live · refreshed every 30 min
Target snapshot
Allr3 (allr3) — Pfizer.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Allr3 TARGET | allr3 | Pfizer | marketed | The pharmacological class of ALLR3 is not specified. | The molecular target of ALLR3 is not specified. |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (The pharmacological class of ALLR3 is not specified. class)
- Pfizer · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Allr3 CI watch — RSS
- Allr3 CI watch — Atom
- Allr3 CI watch — JSON
- Allr3 alone — RSS
- Whole The pharmacological class of ALLR3 is not specified. class — RSS
Cite this brief
Drug Landscape (2026). Allr3 — Competitive Intelligence Brief. https://druglandscape.com/ci/allr3. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab